The reviewed evidence distinguishes the human EXT1–EXT2 catalytic assembly, individual recombinant subunits, tagged cellular localization and database models. The EXT2-partner associations are refined to protein heterodimerization using direct structural evidence; the NDST1 association remains non-core under the campaign instructions. No publication quotations are added. The source-described 746-residue Q16394 product is preserved. Engineered anchor deletions, expression tags, host species and other transcript models are not additional natural products or proof of functional equivalence.
PMID:12907669(https://pubmed.ncbi.nlm.nih.gov/12907669/) was recovered as an author-uploaded original. Operative Methods, Results, relevant captions and selected Discussion were read. Human EXT1 residues 29–746 and EXT2 lacking residues 1–46 were expressed in HEK293 with engineered secretion leaders. Anti-FLAG-bound preparations extend free K5-derived oligosaccharides. Single-donor radiolabel incorporation, chain-length chromatography and linkage-sensitive glycosidase digestion support sugar transfer and polymerization. Apparent 160-kDa EXT1 and associated EXT1–EXT2 elution support oligomerization; the endogenous-partner isoelectric-focusing check is reported but not displayed. Neither physiological secretion nor an obligate native EXT1 homodimer is inferred. No original figure pixels or supplementary material were inspected.
The two modern human studies refine that interpretation:
No modern structural figure pixels, raw spectra or supplementary numerical experiments were independently inspected. Public section/figure locators are given below and in the reference assessments; exact archived read scopes remain available in the provenance record. The older positive GlcNAc-transfer result remains visible alongside the modern differences in constructs, substitutions, stability and assay conditions. Actual chain-extension chemistry supports biosynthetic participation beyond knockout necessity; EXT1 is not assigned every linker or core-protein synthesis step.
PMID:9620772(https://doi.org/10.1038/514) is now available through its author-uploaded original. Construct, HPLC/labeling, IF and endoH Methods, operative Results and captions were read. Human HeLa-derived EXT1 was expressed in mouse/CHO hosts. HS restoration or altered HS profiles are positive; tagged full-length EXT1 shows an ER pattern. Calnexin and glycosidase corroboration include reported-but-undisplayed results. N-terminal deletion and glycosylation support the secretory membrane-protein model without a direct protease-protection topology assay. This supersedes the earlier abstract-only access assessment, not the underlying source record.
PMID:10639137(https://pubmed.ncbi.nlm.nih.gov/10639137/) was likewise recovered as an author-uploaded original. Construct/microscopy/co-IP/sugar-transfer Methods, operative Results, Table 1 and captions were read. Human HeLa-derived EXT1 is tested in BHK or mouse sog9 cells with mouse or bovine EXT2. Figure 2 uses mouse EXT2 and shows redistribution into a Golgi 58K-positive compartment. Figure 3 supports self/hetero-association; Table 1 measures cellular immunoprecipitates, not partner-free EXT1. The HSV assay is a surface-HS surrogate supplemented by biochemical measurements. These actual species/construct distinctions remain separate from the mouse-donor database mapping. No figure pixels were inspected.
PMID:17761672(https://pubmed.ncbi.nlm.nih.gov/17761672/) was read from its author-uploaded original: human-siRNA, metabolic-labeling and chain-analysis Methods, operative Results/captions and selected Discussion. Human EXT1 depletion in HEK293 shortens HS chains and lowers the HS/chondroitin-sulfate ratio. Full-length overexpression constructs are explicitly mouse-brain cDNAs; soluble constructs refer to the prior human study. The Figure 6 localization experiment concerns EXT2. No pixel/supplement inspection is claimed.
Independent ER imaging in PMID:33962942(https://doi.org/10.1126/sciadv.abe8349), Results/Figure 6 caption and microscopy Methods, places tagged EXT1 in ER sheets/tubules in Cos7 using STED/SIM and ER markers. PMID:27229929(https://doi.org/10.1186/s12885-016-2374-2), selected cloning Methods, supplies human-ORFeome v5.1 provenance. This is not independent sequencing of every later fluorescent insert or measurement of endogenous human occupancy. No image pixels or supplementary microscopy were inspected. All four ER-membrane assertions retain the positive historical and newer imaging evidence as a non-core compartment. Tagged ER residence does not establish the principal location of the active elongation complex. The ER pool and active Golgi assembly are compatible. No artifact verdict, universal ER exclusion, new ER-shaping activity or N-glycan catalysis is inferred.
PMID:10679296(https://doi.org/10.1006/bbrc.2000.2219) remains complete-original unavailable despite bounded access attempts. Its positive COS-7 Golgi/oligomerization abstract is preserved, while exact insert, antibody and imported ER protocol are unverified. The reviewed locations and complex have independent original support. PMID:9703997(https://doi.org/10.1006/bbrc.1998.9050) remains abstract-only: it explicitly reports mouse Ext1 and epitope-tagged ER localization, without recovered operative Methods or exact endpoints.
PMID:35137078(https://pmc.ncbi.nlm.nih.gov/articles/PMC9132247/) was read from the complete original XML at relevant Results/Methods, and Figure 7 pixels were inspected. Human full-length EXT1/EXT2 and NDST1 variants carry fluorescent tags in COS-7. Figure 7B includes EXT1/EXT2 and EXT1/NDST1A/B; 7A uses GM130, and 7C restricts FRET to co-expressing cells. This supports cellular proximity/association, not purified affinity or fixed GAGosome stoichiometry. The 882/825-residue distinction concerns NDST1, not EXT1.
The released BioPlex study, PMID:33961781 contains a released 293T interaction-table record for EXT2 Q93063-2 and EXT1 Q16394. That literal isoform label is retained as a historical source mapping; A/B column order is not a bait-direction assignment. HCT116 lacks both target baits and this pair, so absence there is a coverage limit. PMID:40205054(https://pubmed.ncbi.nlm.nih.gov/40205054/) independently supplies an explicit EXT1-bait/EXT2-non-bait interaction in its released NDEx AP–MS network in U2OS (network edge 552868). The relevant original AP–MS Methods were read: human ORFeome C-terminal affinity-tag constructs, anti-HA capture and MS/filtering. The 2025 positive pair comes from AP–MS, not the inspected assembly/AlphaFold supplementary tables. Exact historical insert sequences, purified binary interactions and equivalence to every current product remain unverified. The screen/FRET observations establish association; the independent purified human heterodimer structures supply the specific stoichiometric support for GO:0046982. This refinement does not turn the original screens into structural assays.
The source-node-containing PANTHER PTHR11062 tree places the exact 746-residue human leaf PTN002476064 below PTN000115158 and PTN000869020. Four positive target-path IBD functions and no target-path NOT were verified; self-WITH is valid experimental grounding. The mouse P97464 MSA and ENSMUSP00000076505 sequence also match exactly. Current UniProt instead classifies EXT1 in PTHR48261/SF3; the returned newer-family tree does not contain this target/imported nodes. That version distinction is preserved, without evolutionary-loss inference or treating reciprocal electronic rows as independent experiments.
Actual target InterPro matches include IPR004263/IPR015338/IPR040911. Current ARBA rules match the captured target for ossification, Golgi, HS synthesis and both substrate-specific activities. Current ARBA00028685 has no matching target disjunct; the unresolved historical rule version does not negate independent ER evidence. Official ENZYME 2.4.1.225 agrees with GO:0050509 and lists Q16394. Direct Rhea endpoints returned 403; RHEA:20908 correspondence is checked through official GO/ENZYME, not an unread Rhea body.
The native human Reactome EXT1 participant 2022897 specifies residues 1–746 and its own Golgi-membrane location, distinct from event-level Golgi-lumen labels. Events 2022851/2022856/2076392 reach native complex 2022878 through catalysts 2022845/2022849. Defective-EXT2 events 3656254/3656267/9036289 retain native EXT1. Events 3656257/3656261/9036285 reach defective-EXT1 set 3730938 through complex 9036279. The source frameshift endpoints 250/497 and literal R339L label are preserved; current Q16394 has G339/R340, so that nomenclature is unresolved and is not silently repaired. Native location is independently supported without equating mutant members to canonical protein.
Current GO:0120504 specifically represents EXT1–EXT2. The official ComplexPortal CPX-8307 participant identities are positive, but its GO:0043541 cross-reference denotes the distinct Alg7/Alg13/Alg14 dolichol-linked assembly. The confirmed term correction preserves the source annotation. A separate probable query concerns its prose linkage configurations versus beta-1,4-GlcA/alpha-1,4-GlcNAc chemistry. Neither query rejects the experimentally established complex or invents a qualifier defect; neither has been reported upstream.
Golgi apparatus→Golgi membrane and catalytic complex→EXT1–EXT2 complex are supported hierarchical refinements. Broad polysaccharide/GAG process→HS-proteoglycan biosynthesis and broad GlcNAc transfer→the substrate-specific reaction are explicit lateral corrections, not claimed current ancestor relationships. The free-oligosaccharide assay is distinguished from glypican-associated extension.
PMID:7550340(https://doi.org/10.1038/ng1095-137) remains abstract/subscription-preview only. The human breakpoint/frameshift and skeletal-disease link is positive. It does not resolve EXT1 participation in GO:0001503 bone formation, so both the rule-derived and experimental ossification assertions remain UNDECIDED without the operative original. The matching ARBA rule is preserved as a source fact. The cryo-EM studies establish enzyme chemistry and complex structure, not ossification, and are not cited as positive support for that process. No false-curator or inactivity conclusion is inferred.
EXT1’s principal reaction is beta-1,4 transfer of glucuronic acid from UDP-GlcA to a GlcNAc-terminated chain. Its second measured capacity is alpha-1,4 transfer of GlcNAc from UDP-GlcNAc to a GlcA-terminated acceptor. Both belong to chain elongation by the EXT1–EXT2 complex; these terms do not assign linker synthesis, sulfation or the entire biosynthetic pathway to EXT1.
In PMID:12907669(https://pubmed.ncbi.nlm.nih.gov/12907669/), human EXT1 29–746 and EXT2 lacking residues 1–46 were expressed as secreted tagged proteins in HEK293 cells. Affinity-captured EXT1 gave positive single-sugar radiochemical transfer and alternating extension on K5-derived free oligosaccharides. Glycosidase digestion supported the reported linkages. These are direct catalytic observations, not assays of native membrane-associated stoichiometry. The authors’ isoelectric-focusing argument against substantial endogenous heterocomplex contamination was reported as data not shown. Figure 5 caption and Results describe the single-transfer assay; no new figure-pixel or raw-data inspection was performed for this synthesis.
PMID:36402845(https://pubmed.ncbi.nlm.nih.gov/36402845/) uses human EXT1 29–746/EXT2 47–718 for soluble-complex biochemistry, defined oligosaccharide FACE assays, and separate full-length HeLa knockout/complementation experiments. Both GT-A mutant sets affected GlcNAc transfer, with a modest stability reduction for the EXT1 D565N/D567N preparation. PMID:36593275(https://pubmed.ncbi.nlm.nih.gov/36593275/) uses human EXT1 28–746/EXT2 46–718, glypican and short-acceptor assays, and assigns dominant GlcNAc transfer to EXT2. EXT1 GT-A effects are smaller or variable there. The latter paper also reports low qualitative activity from separately expressed EXT1, whose low yield and extensive proteolysis prevent quantitative equivalence claims. Thus the studies support secondary EXT1 catalytic capacity while leaving its native quantitative contribution open.
The Golgi setting is independently supported by the accepted source evidence. In PMID:35137078(https://pubmed.ncbi.nlm.nih.gov/35137078/), full-length human fluorescent constructs colocalize with GM130 in COS-7 cells (Methods and Figure 7A caption); this is human protein in a nonhuman host. It is separate from native human Reactome participant localization and from the membrane-topology evidence discussed above. No engineered soluble construct is treated as a natural secreted product, and no additional natural product or isoform is invented.
The apparent EXT1 homodimer in PMID:12907669 Figure 6 and tagged self-co-IP in PMID:10639137 Figure 3 provide conditional positive self-association evidence. They do not establish the native catalytic assembly or resolve a homodimer interface. The modern 1:1 structures concern coexpressed, copurified EXT1–EXT2; a lack of homodimer particles there does not invalidate every other expression condition. The self-association annotation therefore remains non-core.
The secondary GlcNAc unit retains a direct molecular-function slot because the older single-donor assay and the modern low qualitative EXT1-only result measure transfer in separately expressed EXT1 preparations, beyond an assembly requirement. Endogenous-partner contamination was not excluded by displayed data in the older study, and the modern preparation was proteolyzed. These limits constrain attribution and quantitative native contribution; they do not justify treating EXT1 as universally inactive. No additional binding core or new annotation is added.